References
- Abdulkareem IH, Blair M (2013). Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J, 54, 79-86. https://doi.org/10.4103/0300-1652.110033
- Brian E, Henderson, Norman H, Lee, Victoria Seewaldt, Hongbing Shen (2012). The influence of race and ethnicity on the biology of cancer. Nature Reviews Cancer, 12, 648-53. https://doi.org/10.1038/nrc3341
- Bergethon K, Shaw AT, Ou SH, et al (2012). ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 30, 863-70. https://doi.org/10.1200/JCO.2011.35.6345
- Bergethon K, Shaw AT, Ou SH, et al (2012). ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 30, 863-70. https://doi.org/10.1200/JCO.2011.35.6345
- Bell DW (2010). Our changing view of the genomic landscape of cancer. J Pathol, 220, 231-43.
- Campbell PJ, Yachida S, Mudie LJ, et al (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109-13. https://doi.org/10.1038/nature09460
- Chaft JE, Arcila ME, Paik PK, et al (2012). Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma: rationale for comprehensive mutation profiling. Mol Cancer Ther, 11, 485-91. https://doi.org/10.1158/1535-7163.MCT-11-0692
- Ding L, Wendl MC, Koboldt DC, Mardis ER (2010). Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet, 19, 188-96. https://doi.org/10.1093/hmg/ddq391
- Ding L, Ellis MJ, Li S, et al (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 464, 999-1005. https://doi.org/10.1038/nature08989
- DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41 https://doi.org/10.3322/caac.21149
- Ding L, Getz G, Wheeler DA, et al (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455, 1069-75. https://doi.org/10.1038/nature07423
- Engelman JA, Zejnullahu K, Gale CM, et al (2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res, 67, 11924-32. https://doi.org/10.1158/0008-5472.CAN-07-1885
- Field JK, Brambilla C, Caporaso N, et al (2002). Consensus statements from the second international lung cancer molecular biomarkers workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol, 21, 369-73.
- Gandara DR, Mack PC, Li T, et al (2009). Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer, 10, 392-4. https://doi.org/10.3816/CLC.2009.n.074
- Gandara DR, Li T, Lara PN, Jr, et al (2012). Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer, 13, 321-5. https://doi.org/10.1016/j.cllc.2012.05.004
- Gonzales AJ, Hook KE, Althaus IW, et al (2008). Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther, 7, 1880-9. https://doi.org/10.1158/1535-7163.MCT-07-2232
- Gainor JF, Shaw AT (2013). Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist, 18, 865-75. https://doi.org/10.1634/theoncologist.2013-0095
- Govindan R, Hammerman PS, Hayes DN, et al (2012). Comprehensive genomic characterization of squamous cell carcinoma of the lung. J Clin Oncol, 30,453s. abstr 7006. https://doi.org/10.1200/JCO.2010.34.2808
- Griffith M, Griffith OL, Mwenifumbo J, et al (2010). Alternative expression analysis by RNA sequencing. Nat Methods, 7, 843-7. https://doi.org/10.1038/nmeth.1503
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
- Jones S, Wang TL, Shih Ie M, et al (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science, 330, 228-31. https://doi.org/10.1126/science.1196333
- Kratz JR, He J, Van Den Eeden SK, et al (2012). A practical molecular assay to predict survival in resected nonsquamous, non-small-cell lung cancer: development and international validation studies. Lancet, 379, 823-32. https://doi.org/10.1016/S0140-6736(11)61941-7
- Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92. https://doi.org/10.1056/NEJMoa044238
- Koivunen JP, Mermel C, Zejnullahu K, et al (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, 14, 4275-83. https://doi.org/10.1158/1078-0432.CCR-08-0168
- Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703. https://doi.org/10.1056/NEJMoa1006448
- Keedy VL, Temin S, Somerfield MR, et al (2011). American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 29, 2121-7. https://doi.org/10.1200/JCO.2010.31.8923
- Keedy VL, Temin S, Somerfield MR, et al (2011). American society of clinical oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 29, 2121-7. https://doi.org/10.1200/JCO.2010.31.8923
- Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703. https://doi.org/10.1056/NEJMoa1006448
- Ley TJ, Mardis ER, Ding L, et al (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72. https://doi.org/10.1038/nature07485
- Lindeman NI, Cagle PT, Beasley MB, et al (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol, 8, 823-59. https://doi.org/10.1097/JTO.0b013e318290868f
- Lee W, Jiang Z, Liu J, et al (2010). The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature, 465, 473-7. https://doi.org/10.1038/nature09004
- Ley TJ, Ding L, Walter MJ, et al (2010). DNMT3A mutations in acute myeloid leukemia. N Engl J Med, 363, 2424-33. https://doi.org/10.1056/NEJMoa1005143
- Larsen JE, Minna JD (2011). Molecular biology of lung cancer: clinical implications. Clin Chest Med, 32, 703-40. https://doi.org/10.1016/j.ccm.2011.08.003
- Morozova O, Marra MA (2008). Applications of next-generation sequencing technologies in functional genomics. Genomics, 92, 255-64. https://doi.org/10.1016/j.ygeno.2008.07.001
- Maher CA, Palanisamy N, Brenner JC, et al (2009). Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA, 106, 12353-8. https://doi.org/10.1073/pnas.0904720106
- Meyerson M, Gabriel S, Getz G (2010). Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet, 11, 685-96. https://doi.org/10.1038/nrg2841
- Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-66. https://doi.org/10.1056/NEJMoa0903840
- Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
- Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8. https://doi.org/10.1016/S1470-2045(09)70364-X
- Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8. https://doi.org/10.1056/NEJMoa0909530
- Marsit CJ, Zheng S, Aldape K, et al (2005). PTEN expression in non-small cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76. https://doi.org/10.1016/j.humpath.2005.05.006
- National Comprehensive Cancer Network: Non-Small Cell Lung Cancer. Version 1.2015. NCCN clinical practice guidelines in oncology. http://www.nccn.com.
- Ozsolak F, Milos PM (2011). RNA sequencing: advances, challenges and opportunities. Nat Rev Genet, 12, 87-98. https://doi.org/10.1038/nrg2934
- Paik PK, Hasanovic A, Wang L, et al (2012). Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol, 30, 481s. abstr 7505.
- Pleasance ED, Cheetham RK, Stephens PJ, et al (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463, 191-6. https://doi.org/10.1038/nature08658
- Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 73. https://doi.org/10.1371/journal.pmed.0020073
- Pao W, Girard N (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12, 175-80. https://doi.org/10.1016/S1470-2045(10)70087-5
- Pfeifer M, Grau M, Lenze D, et al (2013). PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA, 110, 12420-5. https://doi.org/10.1073/pnas.1305656110
- Rosell R, Carcereny E, Gervais R, et al (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 13, 239-46. https://doi.org/10.1016/S1470-2045(11)70393-X
- Rodig SJ, Mino-Kenudson M, Dacic S, et al (2009). Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, 15, 5216-23. https://doi.org/10.1158/1078-0432.CCR-09-0802
- Rimkunas VM, Crosby KE, Li D, et al (2012). Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res, 18, 4449-57. https://doi.org/10.1158/1078-0432.CCR-11-3351
- Sun S, Schiller JH, Spinola M, et al (2007). New molecularly targeted therapies for lung cancer. J Clin Invest, 117, 2740-50. https://doi.org/10.1172/JCI31809
- Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6. https://doi.org/10.1038/nature05945
- Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harborEML4-ALK. J Clin Oncol, 27, 4247-53. https://doi.org/10.1200/JCO.2009.22.6993
- Shaw AT, Yeap BY, Solomon BJ, et al (2011). Effect of crizotinib on overall survival in patients with advanced non-smallcell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol, 12, 1004-12. https://doi.org/10.1016/S1470-2045(11)70232-7
- Stephens PJ, McBride DJ, Lin ML, et al (2009). Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462, 1005-10. https://doi.org/10.1038/nature08645
- Shah SP, Kobel M, Senz J, et al (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med, 360, 2719-29. https://doi.org/10.1056/NEJMoa0902542
- Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61. https://doi.org/10.1158/0008-5472.CAN-08-4055
- Shaw AT, Camidge DR, Engelman JA (2012). Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboringROS1 gene rearrangement. J Clin Oncol, 30, 7508.
- Sasaki T, Rodig SJ, Chirieac LR, et al (2010). The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 46, 1773-80. https://doi.org/10.1016/j.ejca.2010.04.002
- Samuels Y, Wang Z, Bardelli A, et al (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554. https://doi.org/10.1126/science.1096502
- Trigka EA, Levidou G, Saetta AA, et al (2013). A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep, 30, 623-36.
- Thomas A, Rajan A, Lopez-Chavez A, et al (2013). From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol, 24, 577-85. https://doi.org/10.1093/annonc/mds478
- Tang H, Xiao G, Behrens C, et al (2013). A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res, 19, 1577-86. https://doi.org/10.1158/1078-0432.CCR-12-2321
- Takeda H, Takigawa N, Ohashi K, et al (2013). Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res, 319, 417-23. https://doi.org/10.1016/j.yexcr.2012.12.018
- US Food and Drug Administration: FDA approves Xalkori with companion diagnostic for a type of late-state lung cancer. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202570s000ltr.pdf
- Von Hoff DD, Stephenson JJ, Jr, Rosen P, et al (2010). Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol, 20, 4877-883.
- Voelkerding KV, Dames SA, Durtschi JD (2009). Nextgeneration sequencing: from basic research to diagnostics. Clin Chem, 55, 641-58. https://doi.org/10.1373/clinchem.2008.112789
- Wang Z, Gerstein M, Snyder M (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet, 10, 57-63. https://doi.org/10.1038/nrg2484
- Wiegand KC, Shah SP, Al-Agha OM, et al (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med, 363, 1532-43. https://doi.org/10.1056/NEJMoa1008433
- Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
- Zhao Q, Caballero OL, Levy S, et al (2009). Transcriptomeguided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci USA, 106, 1886-91. https://doi.org/10.1073/pnas.0812945106
- Zhu CQ, Ding K, Strumpf D, et al (2010). Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol, 28, 4417-24. https://doi.org/10.1200/JCO.2009.26.4325
- Zhou YM, Liu J, Sun W (2014). MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev, 15, 1391-6. https://doi.org/10.7314/APJCP.2014.15.3.1391